Improving patient outcomes in schizophrenia: achieving remission.
about
In vitro and in vivo demonstration of risperidone implants in mice.Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trialsA one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with SchizophreniaCriteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders.Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders.Remission and recovery during the first outpatient year of the early course of schizophrenia.Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy.Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications.Physical and mental health-related quality of life among older people with schizophrenia.Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa.Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada.Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis.Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations.Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia.Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances.What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
P2860
Q30493152-DD418C80-8E43-41AD-98B2-094118BB7EAFQ33425007-42D48C1E-846D-48BB-887A-80F58AD9E360Q34210712-E68DB081-4837-4485-BA87-7BFE1FF2F3F3Q34444162-F411D41D-CF00-4C56-A870-BB4DA8289109Q35057412-B64DEE35-E33D-45DE-B948-42FD2B50EB16Q35096476-FBCC98A2-EA8C-462D-B5E5-9748AFCA1C1CQ35211161-3AE3D4CF-4DDA-4696-BF11-BB1832C1F29AQ35237264-BF057C91-64A5-46E0-A5CB-EFAD4C18DF7DQ36234891-51269B88-2931-4E25-94E0-8477D882E460Q36582018-110DD879-D35D-4E99-89C9-A3B1851899AAQ36813358-58624D70-8525-4626-AF17-69E83ECAED58Q37187202-A156F28E-B81F-47DA-8D14-66748E5A4C6AQ37616971-FAB1F846-41BC-4325-A98E-9C8C5254FEEEQ41483833-45DE8F7B-F4D7-4EE2-8781-EB7278200D0FQ42650536-336EC52F-DB2F-4DBF-8271-851932F89340Q42659528-C10030F8-EE50-4058-941E-AB8FF014F7CEQ47581504-E8135C80-5579-461B-8888-9434E160BAEBQ49590987-F08BDC5E-BC64-40B0-BB2A-B588A9B7EDABQ50620570-0397FFB9-8280-4744-8520-880E8DC05231Q55556616-BED45655-7152-4F4D-8FC3-5FAC0D5F89E6
P2860
Improving patient outcomes in schizophrenia: achieving remission.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Improving patient outcomes in schizophrenia: achieving remission.
@ast
Improving patient outcomes in schizophrenia: achieving remission.
@en
type
label
Improving patient outcomes in schizophrenia: achieving remission.
@ast
Improving patient outcomes in schizophrenia: achieving remission.
@en
prefLabel
Improving patient outcomes in schizophrenia: achieving remission.
@ast
Improving patient outcomes in schizophrenia: achieving remission.
@en
P2860
P356
P1476
Improving patient outcomes in schizophrenia: achieving remission.
@en
P2093
Henry A Nasrallah
Rob Lasser
P2860
P356
10.1177/1359786806071248
P407
P433
P577
2006-11-01T00:00:00Z